Effect of cancer and cancer treatment on human reproduction

Expert Review of Anticancer Therapy

Volumn 7, Issue 6, 2007, Pages 811-822

  Mitwally, Mohamed F M ^a,b,c,d  

^a Canadian American Reproductive Medicine (CAREM)   (Canada)

^b Reproductive Medicine and Fertility Center ^*  (United States)

^c Reproductive Medicine and Fertility Center (RMFC)   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chemotherapy; Fertility; Radiotherapy; Reproduction

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CLOMIFENE CITRATE; CYCLOPHOSPHAMIDE; CYTOKINE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; GONADORELIN AGONIST; IFOSFAMIDE; INHIBIN B; LOMUSTINE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; THIOTEPA; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

AGE; AMENORRHEA; ARTICLE; AWARENESS; AZOOSPERMIA; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME ABERRATION; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONCEPTION; DIAGNOSTIC ACCURACY; DRUG EFFICACY; EARLY DIAGNOSIS; ECHOGRAPHY; FAMILIAL CANCER; FEMALE INFERTILITY; FETUS MALFORMATION; GAMETOGENESIS; GENETIC DISORDER; GERM CELL; GYNECOLOGICAL EXAMINATION; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HORMONE BLOOD LEVEL; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; MALE INFERTILITY; MALIGNANT NEOPLASTIC DISEASE; MENTAL STRESS; MULTIPLE CYCLE TREATMENT; OOCYTE; ORGAN PRESERVATION; OUTCOMES RESEARCH; OVARY INSUFFICIENCY; PATIENT COUNSELING; PREGNANCY; PRENATAL DRUG EXPOSURE; PROSTATE CANCER; PROSTATECTOMY; REPRODUCTION; RISK ASSESSMENT; SIDE EFFECT; SPERMATOGENESIS; SPERMATOZOON; SPERMATOZOON COUNT; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFERTILITY, FEMALE; INFERTILITY, MALE; MALE; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RADIOTHERAPY; REPRODUCTION;

EID: 34347263354     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.6.811     Document Type: Article

References (91)

1. Maltaris T, Koelbl H, Seufert R, Kiesewetter et al. Gonadal damage and options for fertility preservation in female and male cancer survivors. Asian J. Androl. 8(5), 515-533 (2006).
2. Muller J. Impact of cancer therapy on the reproductive axis. Horm. Res. 59, 12-20 (2003).
3. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med. Pediatr. Oncol. 33, 29-33 (1999).
4. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum. Reprod. Update 7, 394-403 (2001).
5. Simon B, Lee SJ, Partridge AH, Runowicz CD. Preserving fertility after cancer. CA Cancer J. Clin. 55, 211-228 (2005).
6. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 11, 422-434 (2006).
7. Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: a message of hope for young women. Gynecol. Oncol. 103, 1109-1121 (2006).
8. Stern CJ, Toledo MG, Gook DA, Seymour JF. Fertility preservation in female oncology patients. Aust. NZ J. Obstet. Gynaecol. 46, 15-23 (2006).
9. Lee SJ, Schover LR, Partridge AH et al. American society of clinical oncology recommendations on fertility preservation in cancer patients, J. Clin. Oncol. 24, 2917-2931 (2006).
10. Kennedy S, Yudkin P, Greenall M. Cancer in pregnancy. Eur. J. Surg. Oncol. 19, 405-407 (1993).
11. Smith LH, Dalrymple JL, Leiserowitz GS, Danielsen B, Gilbert WM. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am. J. Obstet. Gynecol. 184, 1504-1511 (2001).
12. Antonelli NM, Dotters DJ, Katz VL, Kuller JA. Cancer in pregnancy - a review of the literature. Parts 1 and 2. Obstet. Gynecol. Surv. 51, 125-142 (1996).
13. Agarwal A, Allamaneni SS. Disruption of spermatogenesis by the cancer disease process. J. Natl Cancer Inst. Monogr. 34, 9-12 (2005).
14. Lobo RA. Potential options for preservation of fertility in women. N. Engl. J. Med. 353, 64-73 (2005).
15. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil. Steril. 51, 651-654 (1989).
16. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 428, 145-150 (2004).
17. Johnson M, Everitt BJ. Ovarian function. In: Essential Reproduction. Blackwell Scientific Publications, Oxford, UK, 75-100 (1988).
18. Thomson AB, Critchley HO, Kelnar CJ, Wallace WH. Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation. Best Pract. Res. Clin. Endocrinol. Metab. 16, 311-334 (2002).
19. Shetty G, Meistrich ML. Hormonal approaches to preservation and restoration of male fertility after cancer treatment. J. Natl Cancer Inst. Monogr. 34, 36-39 (2005).
20. Carroll PR, Whitmore WF Jr, Herr HW et al. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy, J. Urol. 137, 420-423 (1987).
21. Meirow D, Schenker JG. Cancer and male infertility. Hum. Reprod. 10, 2017-2022 (1995).
22. Marmor D, Elefant E, Dauchez C, Roux C. Semen analysis in Hodgkin's disease before the onset of treatment. Cancer 57, 1986-1987 (1986).
23. Redman JR, Bajorunas DR, Goldstein MC et al. Semen cryopreservation and artificial insemination for Hodgkin's disease. J. Clin. Oncol. 5, 233-238 (1987).
24. Barr RD, Clark DA, Booth JD. Dyspermia in men with localized Hodgkin's disease. A potentially reversible, immune-mediated disorder. Med. Hypotheses 40, 165-168 (1993).
25. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common development disorder with environmental aspects. Hum. Reprod. 16, 972-978 (2001).
26. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9, 466-472 (2002).
27. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum. Reprod. Update 7, 535-543 (2001).
28. Behringer K, Breuer K, Reineke T et al. Secondary amenorrhea after Hodgkin lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin Lymphoma Study Group. J. Clin. Oncol. 23, 7555-7564 (2005).
29. Katoh MA, Cain KT, Hughes LA, Foxworth LB, Bishop JB, Generoso WM. Female-specific dominant lethal effects na mice. Mutat. Res. 230, 205-217 (1990).
30. Lushbaugh CC, Casarett GW. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 37(Suppl. 2), 1111-1125 (1976).
31. Wallace WH, Shalet SM, Hendry JH, Morris-Jones PH, Gattamaneni HR. Ovarian failure following abdominal irradiation in childhood: the radiosensitivity of the human oocyte. Br. J. Radiol. 62, 995-998 (1989).
32. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. Am. J. Epidemiol. 150, 245-254 (1999).
33. Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J. Natl Cancer Inst. Monogr. 34, 64-68 (2005).
34. Wallace WH, Thomson AB. Preservation of fertility in children treated for cancer. Arch. Dis. Child. 88, 493-496 (2003).
35. Hawkins MM, Smith RA. Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int. J. Cancer 43, 399-402 (1989).
36. Nomura T. Transgenerational effects of radiation and chemicals in mice and humans. J. Radiat. Res. (Tokyo) 47(Suppl. B), 83-97 (2006).
37. Swerdlow AJ, Jacobs PA, Marks A et al. Fertility, reproductive outcomes, and health of offspring, of patients treated for Hodgkin's disease: an investigation including chromosome examinations. Br. J. Cancer 74, 291-296 (1996).
38. Sankila R, Olsen JH, Anderson H et al. Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N. Engl. J. Med. 338, 1339-1344 (1998).
39. Apperley JF, Reddy N. Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev. 9, 93-116 (1995).
40. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum. Reprod. Update 11, 69-89 (2005).
41. Ogilvy-Stuart AL, Clayton PE, Shalet SM. Cranial irradiation and early puberty. J. Clin. Endocrinol. Metab. 78, 1282-1286 (1994).
42. Constine LS, Woolf PD, Cann D et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N. Engl. J. Med. 328, 87-94 (1993).
43. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum. Reprod. Update 7, 394-403 (2001).
44. Sorosky JI, Scott-Conner CE. Breast disease complicating pregnancy. Obstet. Gynecol. Clin. North Am. 25, 353-363 (1998).
45. Gwyn K. Children exposed to chemotherapy in utero. J. Natl Cancer Inst. Monogr. 34, 69-71 (2005).
46. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 5, 283-291 (2004).
47. Benjamin EM. Chemically Induced Birth Defects (2nd Edition). Schardein JL (Ed.). Marcel Dekker, NY, USA (1993).
48. Buekers TE, Lallas TA. Chemotherapy in pregnancy. Obstet. Gynecol. Clin. North Am. 25, 323-329 (1998).
49. Aviles A, Diaz-Maqueo JC, Talavera A et al. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am. J. Hematol. 36, 243-248 (1991).
50. Zemlickis D, Lishner M, Degendorfer P et al. Fetal outcome after in utero exposure to cancer chemotherapy. Arch. Intern. Med. 152, 573-576 (1992).
51. Garber J. Long-term follow-up of children exposed in utero to antineoplastic agents. Semin. Oncol. 16, 437-444 (1989).
52. Caligiuri MA, Mayer RJ. Pregnancy and leukemia, Semin. Oncol. 16, 388-396 (1989).
53. Doll DC, Ringenberg QS, Yarbro JW. Management of cancer during pregnancy. Arch. Intern. Med. 148, 2058-2064 (1988).
54. Doll RC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin. Oncol. 16, 337-346 (1989).
55. Germann N, Goffinet F, Goldwassser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann. Oncol. 15, 146-150 (2004).
56. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk. Lymphoma 33, 65-76 (1999).
57. Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J. Natl Cancer Inst. Monogr. 34, 21-25 (2005).
58. Fenig E, Mishaeli M, Kalish Y, Lishner M. Pregnancy and radiation. Cancer Treat. Rev. 27, 1-7 (2001).
59. Puscheck E, Philip PA, Jeyendran RS. Male fertility preservation and cancer treatment. Cancer Treat. Rev. 30, 173-180 (2004).
60. Brougham MF, Kelnar CJ, Sharpe RM, Wallace HB. Male fertility following childhood cancer: current concepts and future therapies. Asian J. Androl. 5, 325-337 (2003).
61. Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR. Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin. Oncol. (R. Coll. Radiol.) 1, 75-79 (1989).
62. Shalet SM, Didi M, Ogilvy-Stuart AL, Schulga J, Donaldson MD. Growth and endocrine function after bone marrow transplantation. Clin. Endocrinol. (Oxf.) 42, 333-339 (1995).
63. Centola GM, Keller JW, Henzler M, Rubin P. Effect of low-dose testicular irradiation on sperm count and fertility in patients with testicular seminoma. J. Androl. 15, 608-613 (1994).
64. Gordon W Jr, Siegmund K, Stanisic TH et al. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy (SWOG-8711). Southwest Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 38, 83-94 (1997).
65. Socie G, Salooja N, Cohen A et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 101, 3373-3385 (2003).
66. Martin RH, Hildebrand K, Yamamoto J et al. An increased frequency of human sperm chromosomal abnormalities after radiotherapy. Mutat. Res. 174, 219-225 (1986).
67. Fattibene P, Mazzei F, Nuccetelli C, Risica S. Prenatal exposure to ionizing radiation: sources, effects and regulatory aspects. Acta Paediatr. 88, 693-702 (1999).
68. Siimes MA, Rautonen J. Small testicles with impaired production of sperm in adult male survivors of childhood malignancies. Cancer 65, 1303-1306 (1990).
69. Boekelheide K, Schoenfeld HA, Hall SJ et al. Gonadotropin-releasing hormone antagonist (Cetrorelix) therapy fails to protect nonhuman primates (Macaca arctoids) from radiation-induced spermatogenic failure. J. Androl. 26, 222-234 (2005).
70. Wallace EM, Groome NP, Riley SC, Parker AC, Wu FC. Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testosterone secretion: a prospective longitudinal study. J. Clin. Endocrinol. Metab. 82, 3111-3115 (1997).
71. van Rooij IA, Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, Velde ER. Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization. Fertil. Steril. 79, 482-488 (2003).
72. Burger HG, Dudley EC, Hopper JL et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J. Clin. Endocrinol. Metab. 80, 3537-3545 (1995).
73. Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil. Steril. 64, 991-994 (1995).
74. Lee SJ, Lenton EA, Sexton L, Cooke ID. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular menstrual cycles. Hum. Reprod. 3, 851-855 (1988).
75. Muttukrishna S, Knight PG. Inverse effects of activin and inhibin on the synthesis and secretion of FSH and LH by ovine pituitary cells in vitro. J. Mol. Endocrinol. 6, 171-178 (1991).
76. Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia DE, Soules MR. Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J. Clin. Endocrinol. Metab. 81, 2742-2745 (1996).
77. Munz W, Hammadeh ME, Seufert R, Schaffrath M, Schmidt W, Pollow K. Serum inhibin A, inhibin B, pro-α C, and activin A levels in women with idiopathic premature ovarian failure. Fertil. Steril. 82, 760-762 (2004).
78. Seifer DB, Scott RT Jr, Bergh PA et al. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertil. Steril. 72, 63-65 (1999).
79. van Rooij IA, Broekmans FJ. Velde ER et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. 17, 3065-3071 (2002).
80. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 131, 1-9 (2006).
81. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction 124, 601-609 (2002).
82. Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet 2, 645-647 (1987).
83. Hendriks DJ, Broekmans FJ, Bancsi LF, de Jong FH, Looman CW, Te Velde ER. Repeated clomiphene citrate challenge testing in the prediction of outcome in IVF: a comparison with basal markers for ovarian reserve. Hum. Reprod. 20, 163-169 (2005).
84. Sharara FI, Scott RT Jr, Seifer DB. The detection of diminished ovarian reserve in infertile women. Am. J. Obstet. Gynecol. 179, 804-812 (1998).
85. Padilla SL, Bayati J, Garcia JE. Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization. Fertil. Steril. 53, 288-294 (1990).
86. Winslow KL, Toner JP, Brzyski RG, Oehninger SC, Acosta AA, Muasher SJ. The gonadotropin-releasing hormone agonist stimulation test - a sensitive predictor of performance in the flare-up in vitro fertilization cycle. Fertil. Steril. 56, 711-717 (1991).
87. Fabregues F, Balasch J, Creus M et al. Ovarian reserve test with human menopausal gonadotropin as a predictor of in vitro fertilization outcome. J. Assist. Reprod. Genet. 17, 13-19 (2000).
88. Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil. Steril. 69, 505-510 (1998).
89. Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, Te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum. Reprod. 20, 611-615 (2005).
90. Wallace WH, Kelsey TW. Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Hum. Reprod. 19, 1612-1617 (2004).
91. Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD, Velde ER. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil. Steril. 77, 328-336 (2002).